Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Mar 22;11(3):409.
doi: 10.3390/cancers11030409.

The Role of MicroRNAs in Hepatoblastoma Tumors

Affiliations
Review

The Role of MicroRNAs in Hepatoblastoma Tumors

Ion Cristóbal et al. Cancers (Basel). .

Abstract

Hepatoblastoma is the most common hepatic malignancy during childhood. However, little is still known about the molecular mechanisms that govern the development of this disease. This review is focused on the recent advances regarding the study of microRNAs in hepatoblastoma and their substantial contribution to improv our knowledge of the pathogenesis of this disease. We show here that miRNAs represent valuable tools to identify signaling pathways involved in hepatoblastoma progression as well as useful biomarkers and novel molecular targets to develop alternative therapeutic strategies in this disease.

Keywords: biomarkers; hepatoblastoma; microRNA; signaling; therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
MicroRNA biogenesis in mammalian cells. MiRNA genes are transcribed by RNA polymerase to form the immature pri-miRNA, which is cut by Drosha to liberate a pre-miR which is transported by Exportin-5 from the nucleus to the cytoplasm. The pre-miR is then cleaved by Dicer and the mature miR binds to the RNA-induced silencing complex (RISC) and targets a specific mRNA.
Figure 2
Figure 2
MicroRNAs participating in the key signaling pathways involved in the pathogenesis of hepatoblastoma (HB) tumors. DR: downregulated; UR: upregulated.

References

    1. Lim I.I.P., Bondoc A.J., Geller J.I., Tiao G.M. Hepatoblastoma-The Evolution of Biology, Surgery, and Transplantation. Children. 2018;6:1. doi: 10.3390/children6010001. - DOI - PMC - PubMed
    1. Kehm R.D., Osypuk T.L., Poynter J.N., Vock D.M., Spector L.G. Do pregnancy characteristics contribute to rising childhood cancer incidence rates in the United States? Pediatr. Blood Cancer. 2018;65:e26888. doi: 10.1002/pbc.26888. - DOI - PMC - PubMed
    1. Meyers R.L., Maibach R., Hiyama E., Häberle B., Krailo M., Rangaswami A., Aronson D.C., Malogolowkin M.H., Perilongo G., von Schweinitz D., et al. Risk-stratified staging in paediatric hepatoblastoma: A unified analysis from the Children’s Hepatic tumors International Collaboration. Lancet Oncol. 2017;18:122–131. doi: 10.1016/S1470-2045(16)30598-8. - DOI - PMC - PubMed
    1. Bell D., Ranganathan S., Tao J., Monga S.P. Novel advances in understanding of molecular pathogenesis of hepatoblastoma: A Wnt/beta-catenin perspective. Gene Expr. 2017;17:141–154. doi: 10.3727/105221616X693639. - DOI - PMC - PubMed
    1. Sumazin P., Chen Y., Treviño L.R., Sarabia S.F., Hampton O.A., Patel K., Mistretta T.A., Zorman B., Thompson P., Heczey A., et al. Genomic analysis of hepatoblastoma identifies distinct molecular and prognostic subgroups. Hepatology. 2017;65:104–121. doi: 10.1002/hep.28888. - DOI - PubMed

LinkOut - more resources